DEVA HISTORY

1958
DEVA "Doktorlar Ecza ve Alat" (Physcians Drugs and Equipment) Sanayi ve Ticaret A.Ş. was incorporated.
1960
The first manufacturing facility is established in Tünel, Beyoğlu.
1963
Bomonti pharmaceutical plant was opened.
1968
The ampoule plant was set up.
1970
The production of Tetracycline and Oxytetracycline was realized as the first pharmaceutical raw material in Turkey. The title and status of the Company was changed from DEVA "Doktorlar Ecza ve Alat" (Physicians Drugs and Equipment) Sanayi ve Ticaret Anonim Şirketi to Deva Holding A.Ş.
1973
Thr largest pharmaceutical manufacturing facility was purchased from Farmitalia.
1978
Carlo Erba pharmacuitical plant was purchased.
1981
With the production of Gentamicine in its active pharmaceutical ingredient manufacturing facilities, it was lested among 5 establishments to produce this active ingredient throughout the world.
1983
A detergent and cologne factory was set up in İzmit.
1986
The shares of Deva Holding started to be traded on the Istanbul Stock Exchange.
1988
The production of lincomycin (antibiotic) was started at the "pharmaceutical active ingredient" manufacturing facilities.
1991
The foundation of the synthesis plant were laid in Çerkezköy.
1994
ANSA A.Ş. was purchased by Deva Holding, the title of the firm was changed as DEPA A.Ş. With the production of Potassium Clavulanate, the company accomplished being one of only five establishments in the world capable of producing this active ingredient.
2004
Deva Holding ranked among the top 10 pharmaceutical companies of Turkey with USD 120 million slaes on box basis and a market share of 4,6%. The equity capital of the company was increased to TRY 48 million. Amoklavin became the best selling drug of the year in Turkey.
2006
The majorityownership of Deva Holding was transferred to EastPharma Limited, a business venture of GEM Global Equities Management S.A. In connection with this restructuring, Phillip Haas was elected as the new Chairman of the Board of Directors in July 2006.
2007
The company headquarters moved to its new building in Halkalı. Production plant construction was started in çerkezköy and Köseköy İzmit. Representative offices were opened in Georgia, Russia (Moscow), Azerbaijan and Uzbekistan.
2008
50 years of success in the sector was celebrated together with doctors and pharmacists all around Turkey.
2009
R&D center “DEVARGE” was established.
2009
Transition to SAP ERP system was successfully completed.
2010
DEVA signed the AP Contract on Nov 30, 2010 for the takeover of Production Facility at Çerkezköy Organized Ind. Zone – Tekirdağ owned by Zentiva, engaged in manufacturing drug substance with an area of 67.551 m2 with closed area of 18.742 m2 with royalty for manufacture, sales and export of some drug substances manufactured at said Production Facility and 61 personnel working at aforementioned plant together with entire machinery and equipment including all rights.
2010
Transactions as to merger of DEVA Holding with DEVA İlaç Sanayi ve Ticaret A.Ş. by takeover was completed as of December 31, 2010. Due to such merger, its issued capital was increased from 180.000.000 TL to 180.070.656 TL within its registered authorized stock and the entire amount was given to partners of DEVA İlaç Sanayi ve Ticaret A.Ş. apart from DEVA Holding. This merger served the purpose of reaching a more efficient business model and of operational cost saving.
2010
Turkey’s leading drug manufacturer DEVA Holding delivered drug aid package of 412.3 thousand Turkish Liras composed of 31 palettes to Save the Children Germany Organization. Drug aid package to be used to heal the wounds of flood victims and composed of 62.6 thousand of DEVA drugs shall be conveyed by Save The Children Organization to those in need.
2010
DEVA Holding, the leading drug manufacturer in Turkey, delivered its aid package consisting of 1.581 parcels of medicine worth a total of 2.4 million Turkish Liras to the Turkish Red Crescent Society in October and 1.355 parcels to be used to heal the wounds of Pakistan’s flood victims and containing DEVA pharmaceuticals will be distributed to those in need by the Turkish Red Crescent Society. Moreover, it supported Turkish Red Crescent through blood donation over 120 units.
2010
In 2010, DEVA Holding joins with DEVA İlaç Sanayi ve Ticaret A.Ş.
2011
During the ceremony held on February 26, 2011 to grant certificates of R&D Center within the scope of law numbered 5746 and executed by the Ministry of Industry and Trade; Republic of Turkey, DEVA Holding was granted the Certificate of “R&D Center” by The Esteemed Prime Minister Tayyip Erdogan.
2011
DEVA Holding released its product providing cure for allergic skin disease named atopic dermatitis (AD) and atopic eczema (AE) in February. AE detected during childhood by 10-29% is observed by 1-3% in adults while it is more frequently encountered in developed and developing countries. The product manufactured by DEVA Holding in forms of syrup and capsule and as natural dietary supplement was released into service of Turkish Medicine in February.
2011
DEVA's capital increased to 200.000.000 TRY
2011
At the end of 2011, 42 new product development projects have been completed.
2012
In 2012, production facilities of DEVA Holding audited by German Ministry of Health last month received approval of compliance with European GMP (Good Manufacturing Practice)
2012
In 2012, first registration application to FDA has been realized.

DEVA ABOUT US

Active since in 1958, DEVA Holding is one of the deep-rooted medicine manufacturers of Turkey.

With its main scope of business covering manufacturing and marketing of medicines for human use and raw materials, DEVA Holding also produces veterinary drugs, cologne and medical vials.

Majority shares of DEVA Holding were acquired in 2006 by the funds managed by GEM Global Equities Management S.A., an international fund management company, and EastPharma Ltd. was established to take on the management.

Aiming to offer innovative and different products with a high quality experience so that everyone can reach a healthy life on a global scale, to create giant drug brands in fields it competes and become the first preference DEVA Holding ranks at the fourth place and at the sixth place within its industry on box and turnover basis, respectively, according to IMS Health free market data.

DEVA Holding has been creating difference by releasing new products into market every single year.

DEVA Holding places puts emphasize on research and development activities so as to facilitate access by the patients to the medicines they could need. On this respect, DEVA Holdings’ facilities have received GMP (Good Manufacturing) compliance certification in 2012.

With its strong staff composed of more than 130 trained and specialized personnel, and its full-equipped laboratories fitted with the current technology and production sites, DEVA Holding has been developing innovative, novel forms and products with high added value. On the other hand, it has been striving to conduct the R&D activities in accordance with all ethical and legal arrangements so as to satisfy expectations of the respective authorities, to increase accessibility by proving with shelf life elongation efforts that safety, efficacy and quality of the product is not changed, to develop and adapt to production such methods aimed at increasing efficiency for sustainable growth.

DEVA Holding has become a domestic company which realizes the most comprehensive production in Turkey thanks to production facilities established. Carrying on its production in its production facilities located in Çerkezköy, Kartepe and Topkapı, DEVA Holding has an annual production capacity of 500 million boxes of medicine.

Taking the motto "human health is our indispensable priority no matter where they are" as the starting point, DEVA Holding also gives support to social responsibility projects.

DEVA MISSION

Mission

We exist to offer innovative and diversified rang of products with a high quality experience enabling healthy life opportunity to be available to everyone on a global scale.

Vision

To become the first choice by creating robust pharmaceutical brands in the areas we compete in.

Values

Transparency, result orientation, accountability.

Principles

Deva Holding observes its main principles in all its business processes and makes sure they are reflected in all its functions.

Integrity, quality, reliability, customer orientations, adherence to ethical values, independence, employee satisfaction, creativity, entrepreneurship, team work, environmentalism.

DEVA QUALITY CULTURE

QUALITY – CARE & INNOVATION

Deva quality reflects two fundamental principles of CARE and INNOVATION.

We care for our patients, customers, partners, employees and environment in which we manufacture our products. In taking care we provide a secure and ethical supply of products to underpin the DEVA brand and reputation.

We innovate our products, processes and management practices to enable our company to continously improve our service, our market share and to hold a competitive advantage. Through our innovative approaches we are able to maximiseshare holder investments.

QUALITY – CULTURE

Deva quality culture is founded upon the concept of “Right first time”. Each and every employee at Deva adopts it as a principle to ensure patient safety and excellence in operations.

Deva quality culture starts with product research and development and covers all processes from production through to our distribution networks.

QUALITY - SYSTEM

Deva quality management system ensures our care and innovative principles link directly to our quality culture. Our quality management system provides a framework of operational procedures that bring consistency and best practice to all of our manufacturing sites and also satisfies legal requirements and international levels of Good Manufacturing Practice (GMP). Throughout the quality management system risk managment techniques and pragmatic application exists.

QUALITY – UNDERSTANDING

Deva is driven by people with passion and understanding. In all aspects of our products deva employees strive for improvement and to seek out competitive advantage in both Turkey and International markets. Our people are dedicated and determined to match the challenges facing the pharmaceutical markets.

QUALITY – OUTLOOK 2011

Deva has successfully built a world class quality team and developed its system throughout 2010 to meet international quality and compliance standards. In 2011 DEVA has successfully met the audit requirements of local ministry of health regulators and international customers that rely on DEVA as a strategic manufacturing partner.

Our quality principles of care and innovation continue into 2011 with the launch of new innovative products completely developed by DEVA. Successful international inspection for 2011 will also be the focus of the company to open new markets and maximise our care to patients and shareholders.

DEVA MANAGEMENT

Philipp Daniel Haas

President of the Board of Directors and CEO

Philipp Haas, Chairman of Board of Directors and CEO of DEVA Holding, took his MBA with a major in banking from St.Gallen Economy, Law and Business Administration University. He is fluent in German, English, French, Spanish, Portuguese, Italian and Turkish. Philipp D. Haas who has been working as investment advisor and manager since 1992 has a broad experience in the Eastern European countries and Turkey in particular. Having taken part in several restructuring projects in Ukraine and Turkey, Philipp D. Haas acted as member of several board of directors as representative of foreign corporate investors during the 90s, and Rogan Brewery of Ukraine and Net Holding of Turkey may be mentioned among others. Philipp D. Haas who has had a vast experience in pharmaceutical industry has provided funds with pharmaceutical industry advisory and helped them direct their investments into Eastern Europe. These included Slovakopharma which changed its name to Zentiva subsequently. Currently serving as Chairman of Board of Directors of EastPharma Ltd and DEVA Holding, Haas is also Chairman of Board of Directors at VetaşVeterinerveTarımİlaçları A.Ş., Saba İlaçSanayiveTicaret A.Ş., New Life YaşamSigorta A.Ş., EastPharmaİlaçÜretimPazarlama San. ve Tic. A.Ş. and a member of Board of Directors at EastPharmaSarl, LypanosysPteUmited. He has also been holding senior positions in other companies within the Group. Philipp D. Haas is Vice Chairman of the Board of Directors at Pharmaceutical Manufacturers Association of Turkey (TISD).

Mesut Çetin

Vice-Chairman of Board of Directors and CFO

MesutÇetin, Vice Chairman of Board of Directors and CFO of DEVA Holding, worked at GEM Global Equities Management S.A. as executive in charge of operations between 2005 and 2006, and worked at the same group at different positions since 1999 such as analyst and project director. Mesut Çetin, EastPharma Ltd, Vetaş Veteriner Ve Tanm ilaçları A.Ş. ve Saba ilaç Sanayi ve Ticaret .AŞ.'de Yönetim Kurulu Üyesidir. He has also been holding senior positions in other companies within the Group. MesutÇetin graduated from Mathematics department of Boğaziçi University.

Beat Martin Schlagenhauf

Member of the Board of Directors

An independent member of Board directors of DEVA Holding, Beat Schlagenhauf has been acting as investment advisor and portfolio manager via Zurich-Switzerland based Schlagenhauf& Partner Portfolio Management firm owned by him. Before starting his own business in 1987, he worked at Rothschild Bank based in Zurich as portfolio manager and vice chairman for 9 years. Beat Schlagenhauf has been a member of Board of Directors of DEVA Holding since May 2011.

Cüneyt Demirgüreş

Member of the Board of Directors

CüneytDemirgüreş, and Independent Member of the Board of Directors of DEVA Holding, graduated from METU, Department of Electrical and Electronics Engineering followed by MBA in Boğaziçi University, and took Doctorate of Finance in University of Alabama between the years 1990 and 1993. Having assumed senior executive positions in financial institutions including Eczacıbaşı Securities, Demir Investment and Demirbank, Swiss Portfolio Management and Unicredit Securities, Demirgüreş is a member of Board of Directors at Baytur Motorlu Vas.Ticaret A.Ş. and Baylas Otomotiv A.Ş, and an academician at Koç University.

DEVA CONTRIBUTERS

BOĞAZİÇİ (Lemon Cologne)

Boğaziçi Cologne, one of the most sold brands of Turkey in terms of sales figures, has been manufactured At Kartepe Plant. Production capacity of lemon cologne is 3,5 million liters, The brand Boğaziçi is still perceived one of the most prestigious brands in cologne industry. Since 1970, DEVA has been producing cologne under brand name Boğaziçi. Today, colognes in floral forms such as 80° Lemon, Lavender, After Shave are manufactured which attract various consumer groups, 80° Boğaziçi Lemon Cologne continues to be manufactured with the same odor form ever since 1970.

At this production plant, production capacity ratio was 53% in 2010.

VETAS VETERINARY AND AGRICULTURE MEDICALS A.Ş.

Established under the roof of DEVA Holding to deal with production and manufacturing of veterinary and agricultural products, Vetaş, as one of the pioneers in Turkish animal health drugs industry, takes part among the biggest 3 companies of the industry. Vetaş has largest product range with its innovative product scale, which produces high quality solutions in prevention, diagnosis and treatment of the diseases.

The animal farming industry that is very sensitive to seasonal changes was negatively affected by the increase in feed prices and unfavorable climate conditions in 2012. These conditions caused troubles in repayments of animal farming loans by the breeders resulting in sending of valuable breed animals to slaughterhouse and drops in meat and milk prices.

These troubles suffered in the animal farming industry caused the animal health drugs industry suffer a hard year. Considering all developments in the industry at the right time with the right strategies, Vetaş has achieved to maintain its throng position despite the troubles. Vetaş continued in 2012 as it has always done to meet the requirements in every aspect with the advanced technological infrastructure it owns for ensuring healthy, safe and efficient animal food production, by concentrating on new product efforts, it has focused on the projects of expanding its product range in line with the field dynamics.

It carried on organizing technical support and scientific vocational training seminars with the topics “General Approach to Herd Health and Metabolism Diseases” and “Protection and Treatment Protocols in Metabolism Diseases” for vets throughout Turkey. Vetaş became sponsor in the 13th Veterinary Surgery Congress, and was represented as participant in the Herd Health and Management Symposium, and 1st National Milk Summit that was held for the first time in our country.

Within the activities of new product developments and portfolio enrichment, Vetaş obtained 4 new product marketing authorizations and filed applications for marketing authorizations for 4 new products in 2012.

DEVA HOLDING .NZ.

It was established in New Zealand in order to sell and market drugs pertaining to Deva Holding and Vetaş Veteriner ve Tarım İlaçları A.Ş, its subsidiary, in Australia and New Zealand.

Address:
Level 1, 92 Spey Street, Invergargill 9840, New Zealand
Phone: +64 (3) 218 9911
Facsimile: +64 (3) 218 9933
Email address: office@deva.co.nzoffice@deva.co.nz